Last reviewed · How we verify
Arformoterol 25 ųg BID
Arformoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.
Arformoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy, Asthma maintenance therapy.
At a glance
| Generic name | Arformoterol 25 ųg BID |
|---|---|
| Also known as | Brovana, R,R formoterol |
| Sponsor | Sumitomo Pharma America, Inc. |
| Drug class | Long-acting beta-2 agonist (LABA) |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
As the active R-enantiomer of formoterol, arformoterol selectively activates beta-2 adrenergic receptors on bronchial smooth muscle, leading to increased intracellular cAMP and smooth muscle relaxation. This produces sustained bronchodilation lasting approximately 12 hours, making it suitable for twice-daily dosing in chronic obstructive pulmonary disease and asthma management.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
- Asthma maintenance therapy
Common side effects
- Tremor
- Headache
- Palpitations
- Muscle cramps
- Nervousness
- Tachycardia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Arformoterol 25 ųg BID CI brief — competitive landscape report
- Arformoterol 25 ųg BID updates RSS · CI watch RSS
- Sumitomo Pharma America, Inc. portfolio CI